Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Last Close
Jan 14  •  11:58AM ET
1.14
Dollar change
+0.31
Percentage change
37.44
%
Today, 10:01 AMPositive preclinical study results on enhanced CBD bioavailability via oral gel platform drove the sharp intraday surge.
Index- P/E- EPS (ttm)-0.37 Insider Own53.94% Shs Outstand9.44M Perf Week33.92%
Market Cap12.26M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.93M Perf Month13.37%
Enterprise Value14.79M PEG- EPS next Q- Inst Own0.88% Short Float0.79% Perf Quarter-9.84%
Income-4.30M P/S111.45 EPS this Y- Inst Trans7.48% Short Ratio0.03 Perf Half Y-32.65%
Sales0.11M P/B1.11 EPS next Y- ROA- Short Interest0.04M Perf YTD43.12%
Book/sh1.03 P/C53.30 EPS next 5Y- ROE- 52W High4.11 -72.14% Perf Year-43.32%
Cash/sh0.02 P/FCF- EPS past 3/5Y-18.35% - ROIC-41.52% 52W Low0.67 70.90% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y0.09% - Gross Margin-863.65% Volatility10.24% 8.23% Perf 5Y-
Dividend TTM- EV/Sales134.45 EPS Y/Y TTM- Oper. Margin-3267.80% ATR (14)0.10 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.27 Sales Y/Y TTM- Profit Margin-4095.62% RSI (14)67.16 Recom-
Dividend Gr. 3/5Y- - Current Ratio0.27 EPS Q/Q- SMA2032.03% Beta-0.60 Target Price-
Payout- Debt/Eq0.27 Sales Q/Q- SMA5017.82% Rel Volume29.77 Prev Close0.83
Employees18 LT Debt/Eq0.00 Earnings- SMA200-18.03% Avg Volume1.46M Price1.14
IPOOct 29, 2024 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume17,899,324 Change37.44%
Today 09:16AM
05:03AM
Jan-13-26 11:01PM
09:00AM
Dec-16-25 09:05AM
09:15AM Loading…
Dec-09-25 09:15AM
Dec-05-25 10:30AM
Dec-02-25 08:30AM
Nov-24-25 08:30AM
Oct-23-25 09:00AM
Oct-09-25 08:00AM
Sep-12-25 07:30AM
Sep-05-25 11:26AM
10:30AM
Sep-04-25 08:35AM
08:30AM Loading…
Jul-17-25 08:30AM
Jun-10-25 07:30AM
May-03-25 11:00AM
Feb-27-25 08:45AM
Feb-04-25 08:00AM
Jan-24-25 08:00AM
Dec-19-24 08:30AM
Dec-17-24 08:30AM
Dec-09-24 08:30AM
Dec-02-24 08:30AM
Nov-26-24 08:30AM
Nov-12-24 09:00AM
Oct-30-24 10:00AM
Oct-28-24 09:50PM
Gelteq Ltd. operates as a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.